The rising prevalence of Acromegaly Therapeutic Market, a hormonal disorder that leads to the enlargement of bones and tissues, is driving the demand for advanced treatment options, leading to the development of new molecules. Pharmaceutical companies are investing in R&D to develop new formulations and routes of administration of existing drugs, along with developing a strong pipeline of drugs.

The market is expected to grow due to the rising prevalence of genetic and hormonal diseases, including hypopituitarism and endocrine diseases. The market is also supported by technological advancements and favorable government policies, including subsidized medicines for rare diseases.

Get free sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/3656

The somatostatin analogs (SSAs) segment accounted for the largest market share in 2019, and the segment is expected to continue to dominate the market in the future. The SSAs are prescribed as the first-line treatment option by healthcare physicians due to their wide availability and cost-efficiency. The growth hormone receptor antagonist (GHRI) segment currently has only one drug available, Somavert (Pegvisomant) from Pfizer Inc. However, two GHRIs are in the pipeline, developed by Ionis Pharmaceuticals, Inc.

North America accounted for the largest revenue share in 2019, owing to the increasing prevalence of the disease, coupled with favorable government policies. However, the Asia Pacific region is projected to observe the fastest CAGR throughout the forecast period due to growing healthcare spending by countries such as China and India, coupled with increasing investment by pharmaceutical companies.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/3656

The impact of the COVID-19 pandemic on the acromegaly therapeutic market is expected to be optimistic as the drug is considered a first-in-class medication for the treatment of acromegaly. The rising incidence of hormonal diseases is projected to support growth in the future.

The report provides a detailed overview of the parent market, changing market dynamics, in-depth market segmentation, historical, present, and projected market size, recent industry trends and developments, competitive landscape, strategies of key players, potential and sub-segments, and a neutral perspective on market performance. The market is segmented by region, including North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa (MEA).

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/3656

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs

Browse for more reports…